Skip to content

Cost Assistance and Medication Access

Co-Pay Assistance Program

Most eligible patients pay as little as a $0 co-pay for each prescription.

This program is only valid for patients with commercial (also known as private) insurance who are taking the medication for an FDA-approved indication. The program is only valid for the cost of Orenitram and not applicable to any related supplies or other medical expenses associated with administering the product.

TO ENROLL IN THIS PROGRAM, YOUR PATIENTS MUST UNDERSTAND AND AGREE TO COMPLY WITH THE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

Orenitram 90 Day Trial Program logo

90-Day Trial Program

The 90-Day Trial Program allows you to assess how well your eligible* patients tolerate Orenitram at no cost for up to 90 days. See if they’re eligible to enroll in the program.

View Program Details >

Access and Financial Assistance

Helping Patients Determine if They Qualify for United Therapeutics Patient Assistance Programs

ASSIST, the Access Solutions and Support Team, is committed to helping eligible patients:

  • Access their prescribed therapies
  • Navigate insurance coverage
  • Find information on financial assistance and contracted pharmacies

ASSIST Offers Support During the Referral Process

Through ASSIST, the Orenitram Referral Portal allows you to track the status of prescriptions for your patients who have been prescribed Orenitram. Once you prescribe and submit the initial Referral Form, ASSIST will:

  • Obtain any additional information needed from your patients
  • Arrange for a Specialty Pharmacy to provide home medication delivery upon approval
  • Discuss financial assistance options that may be available for patients who qualify

For more information, reach out to an ASSIST advisor at 1-877-UNITHER (1-877-864-8437), Monday through Friday, 8:30 AM to 7:00 PM ET.

Learn More >

TO ENROLL IN THIS PROGRAM, YOUR PATIENTS MUST UNDERSTAND AND AGREE TO COMPLY WITH THE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

Additional Support Resources

Specialty Pharmacy Support

Read about how Specialty Pharmacies may help your patients access Orenitram, schedule nurse visits, and much more.

Archways Program

Discover how a United Therapeutics Virtual Patient Educator may help your patients get started on Orenitram.

Video and Resource Library

To access helpful videos, downloadable resources for patients, and recent publications, visit Video and Resource Library.

*Eligibility for this program is limited to patients with PAH (WHO Group 1) who have never been treated with Orenitram. Patients transitioning from another treprostinil medication are not eligible for this program.

PAH=pulmonary arterial hypertension; WHO=World Health Organization.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

INDICATION

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).